FDA, FTC send message to biologics makers at competition workshop
US drug and antitrust regulators have signalled their intent to crack down on anti-competitive behaviour in the biologics and biosimilar industries, in an effort to bring down prices.
Retirees interest group supports California’s pay-for-delay ban
The AARP has urged the US Court of Appeals for the Ninth Circuit to uphold a newly-formed California law prohibiting the majority of pay-for-delay pharmaceutical settlements.
Par avoids pay-for-delay suit after court accepts payment was ‘fair’
A Virginia judge has approved Par Pharmaceutical’s settlement with a group of direct purchasers, allowing the pharmaceutical company to escape a pay-for-delay lawsuit.
Europol notes ‘worrying trend’ in fake medicines
EU authorities seized €7.9 million worth of counterfeit medicines—including fake cancer drugs, antivirals, and erectile dysfunction medicines—as part of an operation carried out last year.
Gilead to face HIV antitrust claims
Drugmakers including Gilead Sciences must face antitrust claims related to HIV drugs, after the US District Court for the District of Florida on Monday, March 3 refused to fully throw out a class-action suit implicating the company.
Cooley strengthens litigation team with Finnegan duo
Cooley has grown its IP litigation practice with the addition of partners Sanya Sukduang and Jonathan Davies, who will be based in Washington, DC.
Sanofi unit takes CSL to court over haemophilia therapy
Biotech company Bioverativ has accused CSL Behring of infringing three patents covering its haemophilia B treatment Alprolix.
India restricts drug exports, fueling shortage fears
India has imposed export restrictions on drugs and active pharmaceutical ingredients (APIs), including paracetamol, amid fears over COVID-19-related shortages.
Thermo Fisher to buy Qiagen for $11.5bn
Biotech Thermo Fisher Scientific has announced plans to acquire Dutch diagnostics group Qiagen for $11.5 billion.
Sheppard patent lawyer joins McDermott Will & Emery’s IP practice
April Weisbruch has joined McDermott Will & Emery as an IP partner, moving from Sheppard Mullin Richter & Hampton, where she worked as an IP associate.
